Turn Therapeutics【TTRX】銘柄情報

Turn Therapeutics Inc (TTRX) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

6.02

( -6.23% )

買値

5.54

売値

6.50

出来高

91,509

5.51 日の範囲 6.30

2.5701 52 週間の範囲 26.50

時価総額

179.324M

前日終値

6.42

始値

6.30

時刻

5.51

最終取引時間

財務取引量

US$ 541,622

VWAP

5.9188

平均取引量 (3 か月)

US$ 22,073

発行済株式数

29,788,040

配当利回り

PER

-28.67

1 株当たり利益 (EPS)

-0.13

歳入

純利益

-3.84M

Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to c... Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. The company was formerly known as Global Health Solutions, Inc and change its name to Turn Therapeutics Inc. in September 2025. Turn Therapeutics Inc. was incorporated in 2015 and is based in Westlake Village, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

turntherapeutics.com

本社

Westlake Village, United States

設立

2026

Turn Therapeutics Inc is listed in the Healthcare sector of the ナスダック市場 with ticker TTRX. The last closing price for Turn Therapeutics was US$6.42. Over the last year, Turn Therapeutics shares have traded in a share price range of US$ 2.5701 to US$ 26.50.

Turn Therapeutics currently has 29,788,040 shares in issue. The market capitalisation of Turn Therapeutics is US$179.32 million. Turn Therapeutics has a price to earnings ratio (PE ratio) of -28.67.

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks...

Form 8-K - Current report

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

Study demonstrates statistically significant reduction in disease severity in a murine dermatitis model characterized by IL-36 expression First...

Form 8-K - Current report

Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin...

Form 8-K - Current report

Turn Therapeutics Appoints Physician-Scientist and Former FDA Commissioner, Dr. Stephen M. Hahn, as Executive Clinical and Regulatory Lead

Dr. Hahn Brings Unparalleled Clinical and Regulatory Expertise to Support Advancement of GX-03 for Moderate-to-Severe Atopic Dermatitis and...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.55	10.0548446069	5.47	6.75	4.57	104338	5.96346457	CS
4	2.34	63.5869565217	3.68	6.75	3.66	59081	5.24857014	CS
12	2.47	69.5774647887	3.55	6.75	3.01	35127	4.43487015	CS
26	2.48	70.0564971751	3.54	6.75	2.7	41339	4.09745524	CS
52	-18.58	-75.5284552846	24.6	26.5	2.5701	190599	7.49311911	CS
156	-18.58	-75.5284552846	24.6	26.5	2.5701	190599	7.49311911	CS
260	-18.58	-75.5284552846	24.6	26.5	2.5701	190599	7.49311911	CS